RevLite SI Melasma Relapse Rate: Why Studies Report Both 18.8% and 50%
Where You Start Counting Relapse Changes the Number
A randomized, double-blind, split-face trial in 16 Asian women treated one side of the same face with a 1064nm picosecond laser and the other with Revlite SI. Each side received three sessions four weeks apart, with follow-up out to six months. Two evaluators, both blinded to which side got which device, scored standardized photographs, and their inter-rater agreement came in at 0.870.
In this study, the relapse rate depends entirely on which baseline you count from. Using the pre-specified definition, relapse against the score measured just before the third session, and defining relapse as at least 20 percent worsening, the Q-switched side relapsed in 18.8 percent of cases and the picosecond side in 12.5 percent. Recalculated against each patient’s best score at any point during follow-up, the six-month relapse rate came out to 50 percent on both sides.
Same patients, same photographs, same scoring sheet, and a single change in baseline pulled the numbers far apart. The gap is a measurement convention, not a verdict on which device performs better, and the paper reports both definitions while noting that the direction of the difference between devices did not change. Any relapse figure cited without its reference point is not really usable for comparison.
What the Maker’s Documentation Discloses, and What It Doesn’t
Revlite SI is a Q-switched Nd:YAG platform from Cynosure Conbio, and the product page describes it as delivering two wavelengths, 1064nm and 532nm. It is marketed as a non-ablative device for pigmented lesions, fine lines, and multicolored tattoos, with melasma listed under the pigmented-lesion category. That is the manufacturer’s own description, and it should be read separately from the indications that actually appear in country-specific regulatory approvals.
The handpiece specifications are laid out in reasonably concrete terms. The SI handpiece is described as adjusting spot size in 0.1mm increments and automatically recognizing whichever handpiece is attached. For smaller pigmented lesions that call for lower fluence, the documentation directs users to the 532nm handpiece.
What the documentation does not say is just as notable. Automatic recognition is described as identifying the handpiece, not as making treatment-parameter decisions on the operator’s behalf, and the statement that local anesthesia is not typically required is an operational note, not a pain measurement. No histological evidence or comparative clinical data appears on that page.
What a Twice-Split Pulse Is Aiming For
PTP fires two pulses in rapid succession within a single Q-switching cycle. The manufacturer describes it as delivering more energy through two pulses separated by microseconds, designed to improve patient comfort. The research literature puts that interval at 100 to 130 microseconds and describes a single Q-switched pulse width of around 20 nanoseconds.
Each individual pulse carries less energy than a single-pulse shot, but because the interval is so short, their peak energies overlap at the moment they strike melanosomes. The literature describes this as delivering up to 60 percent higher peak energy than a single beam, while a separate figure of up to 123 percent higher instantaneous peak comes from the manufacturer data for a different device cited within that same study. The two numbers should not be read as specifications of one device.
Low-fluence toning rests on repeatedly irradiating a wide spot at sub-thermolytic fluence below 5J/cm². Under those conditions, the literature proposes subcellular selective photothermolysis as the mechanism, dispersing melanosomes without destroying the melanocyte itself. Because each session stays below the destructive threshold, the same literature notes that repeated treatment over several months is inherent to the approach.
The Five-Session Improvement Rate Came From a Different PTP Device
The best-known single-arm trial of PTP toning treated 22 Korean women five times at two-week intervals. Using a 7mm spot at 2.5J/cm² fluence, each session delivered an average of 2,914 shots, with no anesthesia, and mild erythema as the treatment endpoint. Notably, the device used in this study was not Revlite but a different PTP device; Revlite is mentioned in the same paper only as another device capable of PTP.
MASI scores dropped from 5.46 to 4.35, a reduction the abstract reports as 20.4 percent and the body text as 20.3 percent. Colorimeter-measured brightness improved by 1.3 points. Investigator assessment rated 59.1 percent of patients as significantly improved, while patient self-assessment put that figure at 86.4 percent, a substantial gap in how the same faces were judged depending on who was judging.
The limitations matter here too. Four of the 22 patients actually saw their MASI scores worsen, and the single-arm design without a control group relied on prior studies as a historical comparison. Erythema, dryness, and itching appeared in some patients but resolved within 24 hours without additional treatment, and across roughly 3,000 shots per session, no serious adverse events such as guttate hypopigmentation were reported. Relapse and long-term course, however, were not tracked in this study.
A Comparison Where Only Pain Scores Differed Leaves a Question
In the split-face trial, the Revlite SI side received about 1,000 shots at 8mm and 2.0 to 2.3J/cm², followed by about 1,000 more at 6mm and 2.5 to 3.0J/cm², a setup that in part ran hotter than the 2.5J/cm² used in the five-session toning study above. Both devices produced a statistically significant reduction in severity over time.
At three months, hemi-mMASI fell from 3.70 to 2.46 on the Q-switched side and from 3.37 to 2.14 on the picosecond side, then rebounded to 2.74 and 2.38 respectively by six months. Repeated-measures ANOVA found no significant main effect for device, and overall aesthetic improvement scores, 2.56 for Q-switched versus 2.38 for picosecond, likewise showed no confirmed difference. The one measure that did split statistically was pain immediately after the first session, where the picosecond side scored lower.
Failing to detect a difference is not the same claim as proving the two devices are equivalent. This was a superiority trial designed around 16 participants, not a study built to demonstrate equivalence. What happens beyond six months, how the curve changes with more sessions, and what each country’s regulatory record actually lists as indications are questions these two papers do not answer.
Entities covered in this article
Sources checked
- Q Switch Laser | RevLite SI® | Cynosure
- Treatment of Melasma with the Photoacoustic Twin Pulse Mode of Low-Fluence 1,064 nm Q-Switched Nd:YAG Laser
- Comparison of 1064‐nm Picosecond and Q‐Switched Neodymium‐Doped Yttrium Aluminum Garnet Lasers for Melasma in Asian Women: A Randomized Double‐Blind Split‐Face Trial
Scope — This article explains devices and technology. It does not provide individual diagnosis or treatment advice.